| Non-Alcoholic Fatty Liver Disease |
1 |
1 |
| Obesity |
0 |
0.89 |
| Biliary Disease |
0 |
0.74 |
| Metabolic Syndrome |
0 |
0.74 |
| Lipids Management |
0 |
0.99 |
| Fatty Liver |
0 |
0.68 |
| Liver |
0 |
0.62 |
| Weight Loss |
0 |
0.62 |
| Liver Disease |
0 |
0.56 |
| Weight Management |
0 |
0.54 |
| Body Mass Index |
0 |
0.17 |
| Cardiovascular Risk Management |
0 |
0.16 |
| Adverse Effects |
0 |
0.11 |
| Clinical Research |
0 |
0.11 |
| Incretin Hormone |
0 |
0.11 |
| Nausea |
0 |
0.11 |
| Healthcare and Medical Technology |
0 |
0.1 |
| High Density Lipoprotein (HDL) cholesterol |
0 |
0.1 |
| LDL Cholesterol |
0 |
0.1 |
| Patient Safety |
0 |
0.1 |
| Apolipoproteins |
0 |
0.06 |
| Europe |
0 |
0.06 |
| Insulin Resistance |
0 |
0.06 |
| Lipoproteins |
0 |
0.06 |
| Magnetic Resonance Imaging |
0 |
0.06 |
| Texas |
0 |
0.06 |
| Triglycerides |
0 |
0.06 |
| Constipation |
0 |
0.05 |
| Diarrhea |
0 |
0.05 |
| Seasonal Affective Disorder |
0 |
0.05 |